Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3

Sun, 12 Apr 2026 03:20:13 +0000
Intellectual Property

USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.